George Church-endorsed startup seeks 'alternatives'; DOJ closes Onpattro marketing investigation
NeuBase is putting up the “For Sale” sign, roughly 10 months after laying off most of its employees.
The Dietrich Stephan biotech, whose gene editing advisory board is chaired by George Church, said it would explore “strategic alternatives” while halting all drug development, according to a press release. NeuBase did not set a timetable for any potential move and noted in the release that it can’t say for certain a deal will be completed “on attractive terms, if at all.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
